Vasodilator therapy for primary pulmonary hypertension. Limitations and hazards

M. Packer

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

Vasodilator drugs were initially administered to patients with primary pulmonary hypertension based on the unproven hypothesis that pulmonary vasoconstriction played an important role in the pathogenesis of the disease. There were early reports of hemodynamic and clinical improvement after treatment with various vasodilating agents, but subsequent experience did not confirm these uncontrolled observations, and emphasized the limitations and hazards of this approach. Vasodilator therapy generally fails to reduce pulmonary vascular resistance selectively during long-term administration and frequently leads to systemic hypotension, exacerbation of the pulmonary hypertensive state, worsening of right ventricular failure, and systemic arterial desaturation. Beneficial hemodynamic responses are seen in only 15% to 25% of patients. Vasodilator therapy should not be considered an established treatment of patients with primary pulmonary hypertension.

Original languageEnglish (US)
Pages (from-to)258-270
Number of pages13
JournalAnnals of Internal Medicine
Volume103
Issue number2
StatePublished - 1985

Fingerprint

Vasodilator Agents
Hemodynamics
Lung
Therapeutics
Vasoconstriction
Vascular Resistance
Hypotension
Familial Primary Pulmonary Hypertension

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Vasodilator therapy for primary pulmonary hypertension. Limitations and hazards. / Packer, M.

In: Annals of Internal Medicine, Vol. 103, No. 2, 1985, p. 258-270.

Research output: Contribution to journalArticle

@article{02fdceae57754da59d2af745939e9f92,
title = "Vasodilator therapy for primary pulmonary hypertension. Limitations and hazards",
abstract = "Vasodilator drugs were initially administered to patients with primary pulmonary hypertension based on the unproven hypothesis that pulmonary vasoconstriction played an important role in the pathogenesis of the disease. There were early reports of hemodynamic and clinical improvement after treatment with various vasodilating agents, but subsequent experience did not confirm these uncontrolled observations, and emphasized the limitations and hazards of this approach. Vasodilator therapy generally fails to reduce pulmonary vascular resistance selectively during long-term administration and frequently leads to systemic hypotension, exacerbation of the pulmonary hypertensive state, worsening of right ventricular failure, and systemic arterial desaturation. Beneficial hemodynamic responses are seen in only 15{\%} to 25{\%} of patients. Vasodilator therapy should not be considered an established treatment of patients with primary pulmonary hypertension.",
author = "M. Packer",
year = "1985",
language = "English (US)",
volume = "103",
pages = "258--270",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "2",

}

TY - JOUR

T1 - Vasodilator therapy for primary pulmonary hypertension. Limitations and hazards

AU - Packer, M.

PY - 1985

Y1 - 1985

N2 - Vasodilator drugs were initially administered to patients with primary pulmonary hypertension based on the unproven hypothesis that pulmonary vasoconstriction played an important role in the pathogenesis of the disease. There were early reports of hemodynamic and clinical improvement after treatment with various vasodilating agents, but subsequent experience did not confirm these uncontrolled observations, and emphasized the limitations and hazards of this approach. Vasodilator therapy generally fails to reduce pulmonary vascular resistance selectively during long-term administration and frequently leads to systemic hypotension, exacerbation of the pulmonary hypertensive state, worsening of right ventricular failure, and systemic arterial desaturation. Beneficial hemodynamic responses are seen in only 15% to 25% of patients. Vasodilator therapy should not be considered an established treatment of patients with primary pulmonary hypertension.

AB - Vasodilator drugs were initially administered to patients with primary pulmonary hypertension based on the unproven hypothesis that pulmonary vasoconstriction played an important role in the pathogenesis of the disease. There were early reports of hemodynamic and clinical improvement after treatment with various vasodilating agents, but subsequent experience did not confirm these uncontrolled observations, and emphasized the limitations and hazards of this approach. Vasodilator therapy generally fails to reduce pulmonary vascular resistance selectively during long-term administration and frequently leads to systemic hypotension, exacerbation of the pulmonary hypertensive state, worsening of right ventricular failure, and systemic arterial desaturation. Beneficial hemodynamic responses are seen in only 15% to 25% of patients. Vasodilator therapy should not be considered an established treatment of patients with primary pulmonary hypertension.

UR - http://www.scopus.com/inward/record.url?scp=0021791023&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021791023&partnerID=8YFLogxK

M3 - Article

VL - 103

SP - 258

EP - 270

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 2

ER -